Human MMP-13 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB511
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Leu20-Cys471
Accession # P45452
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human MMP-13 Antibody
MMP‑13 in MDA‑MB‑231 Human Cell Line.
MMP-13 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using Human MMP-13 Monoclonal Antibody (Catalog # MAB511) at 5 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 493-conjugated Anti-Mouse IgG Secondary Antibody (green; Catalog # NL009) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.MMP-13 in Human Ovarian Cancer Tissue.
MMP-13 was detected in immersion fixed paraffin-embedded sections of human ovarian cancer tissue using 8 µg/mL Mouse Anti-Human MMP-13 Monoclonal Antibody (Catalog # MAB511) overnight at 4 °C. Tissue was stained with the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.Detection of Canine MMP-13 by Western Blot
Effects of IGF-1 or/and PDGF-bb on IL-1 beta-induced NF-kappa B-dependent pro-inflammatory, pro-apoptotic and matrix degrading gene products in chondrocytes.To determine whether IGF-1 or/and PDGF-bbexert effects on IL-1 beta-induced NF-kappa B-dependent expression of pro-inflammatory, pro-apoptotic and matrix degrading gene products, primary chondrocytes were either stimulated with 10 ng/ml IL-1 beta, 10 ng/ml PDGF-bb, 10 ng/ml IGF-1 or combination of both growth factors (5 ng/ml each) or pre-stimulated for 12 h with 10 ng/ml PDGF-bb, 10 ng/ml IGF-1 or combination of both growth factors (5 ng/ml each) followed by 10 ng/ml IL-1 beta for 24. Equal amounts of total proteins were separated by SDS-PAGE and analyzed by immunoblotting using antibodies raised against COX-2, MMP-9 and MMP-13 and active caspase-3. Stimulation with IL-1 beta resulted in production of COX-2, MMP-9, MMP-13 and caspase-3 cleavage. Pre-treatment with a combination of both IGF-1 or/and PDGF-bb downregulated COX-2, MMP-9, MMP-13 and cleaved caspase-3. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0028663), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human MMP-13 Antibody
Immunoaffinity Purification
Immunocytochemistry
Sample: Immersion fixed MDA-MB-231 human breast cancer cell line
Immunohistochemistry
Sample: Immersion fixed paraffin-embedded sections of human ovarian cancer tissue
Immunoprecipitation
Sample: Conditioned cell culture medium spiked with Recombinant Human MMP‑13 (Catalog # 511‑MM), see our available Western blot detection antibodies
Western Blot
Sample: Recombinant Human MMP-13 Western Blot Standard (Catalog # WBC020)
Reviewed Applications
Read 6 reviews rated 4.7 using MAB511 in the following applications:
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: MMP-13
Matrix metalloproteinases are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix. MMP-13 (Collagenase-3) has been demonstrated to degrade a range of extracellular matrix proteins, including collagen types I, II, III, IV, IX, X and XIV, gelatin, aggrecan, perlecan and fibronectin. MMP-13 is distinguished from the other human collagenases by its effecient degradation of type II collagen. MMP-13 is expressed by fibroblasts, chrondrocytes and squamous epithelial cells. Structurally, MMP-13 may be divided into several distinct domains; a pro-domain which is cleaved upon activation; a catalytic domain containing the zinc binding site; a short hinge region and a carboxyl terminal (hemopexin-like) domain.
References
- Jeffery, J.J. (1998) in Collagenase 3. A.J. Barrett, et al. (eds): Handbook of Proteolytic Enzymes, San Diego: Academic Press, p. 1167.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional MMP-13 Products
Product Documents for Human MMP-13 Antibody
Product Specific Notices for Human MMP-13 Antibody
For research use only